OICR enters collaboration with Janssen Inc. in the development of multi-centre clinical trials to identify improved prostate cancer biomarkers

TORONTO, ON (April 22, 2013) — Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced a collaboration with Janssen Inc. to find and test new biomarkers to identify patients with hormone resistant prostate cancer at high risk for disease progression and biomarkers of response to therapy. These biomarkers… Continue reading OICR enters collaboration with Janssen Inc. in the development of multi-centre clinical trials to identify improved prostate cancer biomarkers

Merck Invests In Pan-canadian Life Sciences Research Innovation Sector

A $4-million public-private partnership will promote research innovation involving three academic commercialization centres in Canada   CHICAGO, Illinois – April 22, 2013 – Merck Canada will be announcing today at the BIO International Convention that it is reinforcing its commitment to the Canadian life sciences research innovation sector. Merck will provide $4 million in funding to the Institute for Research in Immunology and… Continue reading Merck Invests In Pan-canadian Life Sciences Research Innovation Sector